Biomarin Pharmaceutical (BMRN) Work In Process (2010 - 2021)
Biomarin Pharmaceutical's (BMRN) quarterly Work In Process came in at $412.4 million in Q3 2021, up 39.01% YoY from $296.7 million in Q3 2020, and up 10.29% on a QoQ basis from $374.0 million in Q2 2021.
Biomarin Pharmaceutical (BMRN) Work In Process (2010 - 2021) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 12 years of Work In Process data on file, last reported at $412.4 million in Q3 2021.
- Quarterly Work In Process rose 39.01% year-over-year to $412.4 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $412.4 million (up 39.01% YoY) and the FY2020 annual result came in at $308.3 million, down 11.91% from the prior year.
- Work In Process rose to $412.4 million in Q3 2021, from $374.0 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $412.4 million in Q3 2021 to a low of $194.6 million in Q1 2018.
- A 5-year average of $295.3 million and a median of $296.7 million in 2020 frame the typical range for Work In Process.
- Annual changes were most pronounced in 2019 — Work In Process surged 51.46% — and 2020, when it slipped 11.91%.
- Tracing BMRN's Work In Process over 5 years: stood at $234.7 million in 2017, then retreated by 1.54% to $231.1 million in 2018, then surged by 51.46% to $350.0 million in 2019, then decreased by 11.91% to $308.3 million in 2020, then jumped by 33.78% to $412.4 million in 2021.
- The last three Work In Process figures came in at $412.4 million (Q3 2021), $374.0 million (Q2 2021), and $355.8 million (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 412.43 Mn |
| Jun 30, 2021 | 373.95 Mn |
| Mar 31, 2021 | 355.76 Mn |
| Dec 31, 2020 | 308.29 Mn |
| Sep 30, 2020 | 296.69 Mn |
| Jun 30, 2020 | 370.15 Mn |
| Mar 31, 2020 | 371.96 Mn |
| Dec 31, 2019 | 349.98 Mn |
| Sep 30, 2019 | 321.07 Mn |
| Jun 30, 2019 | 303.23 Mn |
| Mar 31, 2019 | 282.80 Mn |
| Dec 31, 2018 | 231.06 Mn |
| Sep 30, 2018 | 248.15 Mn |
| Jun 30, 2018 | 234.37 Mn |
| Mar 31, 2018 | 194.58 Mn |
| Dec 31, 2017 | 234.67 Mn |
| Sep 30, 2017 | 262.84 Mn |
| Jun 30, 2017 | 253.66 Mn |
| Mar 31, 2017 | 204.38 Mn |
| Dec 31, 2016 | 167.79 Mn |